ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA
|
|
- Jared Davis
- 5 years ago
- Views:
Transcription
1 ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA
2 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions and expectations that involve uncertainties or risks. These uncertainties and risks include, but are not limited to, those described in the filings we make with the U.S. Securities and Exchange Commission (SEC). Actual results may differ materially from anticipated results. Forward-looking statements are made as of today's date, and we undertake no duty to update them or any of the information contained in this presentation ADA Orlando, FL 2
3 HOOMAN HAKAMI EXECUTIVE VICE PRESIDENT & PRESIDENT DIABETES GROUP 2018 ADA Orlando, FL 3
4 DIABETES GROUP EXECUTIVE SUMMARY Strong legacy & brand highest share position in almost a decade In many ways, just getting started Above corporate average growth Sensor pull-through & conversion of MDI in core pump BU Launch of stand-alone CGM targeting $1B+ category growing 30% Sustainability of growth High differentiation & profitability we ve dramatically improved Innovation in decision support & patient engagement Outcomes focus in products & goto-market 2018 ADA Orlando, FL 4
5 DIABETES STRUCTURE & OPERATING FRAMEWORK REPOSITIONING THE BUSINESS FOR ABOVE CORPORATE AVERAGE GROWTH PRODUCT LINE DIVISION GROUP Administrator Focus Disease / IPU Focused Advanced Insulin Management (AIM) Insulin pump therapy systems Integrated CGM Consumables & accessories Diabetes Group Multiple Daily Injection Solutions (MDIS) Standalone CGM Injection port Diabetes mgmt. programs & services Emerging Technologies Non-Intensive Diabetes Therapies (NDT) Professional CGM Diabetes mgmt. programs & services Diabetes mgmt. programs & services 2018 ADA Orlando, FL 5
6 EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT DISEASE STATE TYPE 2 TYPE 1 REGIMEN PREVALENCE DIET & EXERCISE 60MM ORALS 110MM BASAL 20MM PREMIX 15MM MDI 20MM PUMPS 1.1MM AIM AIM Advanced Insulin Management Patients Served: T1D & T2D on pumps Call point: Endocrinologists Solutions: Insulin pump therapy, consumables & accessories GOAL Artificial Pancreas as standard of care Core business Pumps & CGM ~70% global share 8% penetrated 2018 ADA Orlando, FL 6
7 THE MINIMED 670G SYSTEM NOW APPROVED FOR CHILDREN 7+ Features our most advanced SmartGuard technology, which constantly self-adjusts to allow patients to spend more Time in Range (TIR) Includes our newest and most accurate Guardian TM Sensor ADA Orlando, FL 7
8 NEW CE MARK! THE MINIMED 670G SYSTEM FOR CHILDREN 7+ Advances the ability to automatically suspend & resume insulin delivery to the next level by automating self-adjusting basal insulin every 5 minutes providing the most advanced algorithm that proactively drives Time in Range improvement ADA Orlando, FL 8
9 VALUE-BASED HEALTHCARE PARTNERSHIP PREFERRED PARTNERSHIP STATISTICS Share Revenue EBITA From To 70% 92% VALUE BASED HEALTHCARE AGREEMENT COHORTS: PATIENTS ON PUMP THERAPY Year 1 COMPARISON GROUP: MDI PATIENTS OUTCOME MEASURES: HOSPITALIZATIONS & TOTAL COST 27% REDUCTION IN PREVENTABLE HOSPITALIZATIONS UP TO 14% REDUCTION IN TOTAL MEDICAL COSTS SHARED SAVINGS BETWEEN UHG & MEDTRONIC Investor ADA Orlando, Day FL 9 9
10 THE NEW MINIMED TM 670G SYSTEM PERFORMANCE GUARANTEE FLAT REIMBURSEMENT MODEL TO MITIGATE HOSPITAL COSTS The MiniMed TM 670G System Performance Guarantee $25,000 total reimbursement value per patient over 4 years Year 1 Year 2 Year 3 New program for payers Diabetes-related Inpatient Hospitalization $6000 Inpatient hospitalization claim coded DRG of 637, 638, or 639 (E1010-E109) Diabetes-related Emergency Room Admission $2500 ER visit coded with primary ICD-10 diagnosis of E10* type 1 diabetes, as specified by 2018 CMS ICD-10-CM 2018 ADA Orlando, FL 10
11 DISRUPTIVE CLOSED LOOP ECOSYSTEM Launched Near Long GOALS ALGORITHM MM670G System Outcomes Peds indication Advanced HCL Auto-correction bolus >80% TIR goal Personalized CL Advanced adaptation >85% TIR goal Limited patient interaction SENSOR Guardian Sensor 3 Arm labeling 9% MARD Project Harmony Adaptive cals & non-adjunctive Project Unity Miniaturization, no cals, d wear, disposable Wear & forget USABILITY CareLink Web-based data mgmt. SmartPhone App Data viewing & pump control Project Duo Integrated canula & sensor Simple & discreet INSIGHTS System Performance Report Data-guided system & behavior optimization Virtual Support Augmented assistance & AI guided optimization Proactive Triage Customer Service & HCP preventative mgmt Differentiated Outcomes Note: future concepts; not investigational nor commercially available 2018 ADA Orlando, FL 11
12 LAURA STOLTENBERG VICE PRESIDENT & GM MULTIPLE DAILY INJECTION SOLUTIONS 2018 ADA Orlando, FL 12
13 EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT DISEASE STATE REGIMEN PREVALENCE DIET & EXERCISE 60MM ORALS 110MM TYPE 2 BASAL 20MM PREMIX 15MM MDIS MDI 20MM TYPE 1 PUMPS 1.1MM Adjacent category MDIS Multiple Daily Injection Solutions Patients Served: T1D & T2D on multiple daily injections Call point: Insulin prescribing PCPs/GPs & Endos Solutions: Standalone CGM, injection port GOAL Smart, connected solutions that empower patients & help drive outcomes Personal CGM <5% share ~20% penetrated MDIS Solutions Therapy Innovation Decision Support Patient Engagement 2018 ADA Orlando, FL 13
14 GUARDIAN TM CONNECT WITH SUGAR.IQ LAUNCHING THE MDIS BUSINESS Expanding Access First stand-alone CGM launched 20MM MDI patients globally Empowering Patients with Smarter Tools Predictive alerts + Sugar.IQ Insights No dedicated receiver 12 month transmitter Arm indication enhanced accuracy (9.1% MARD) Designed to Help Improve Outcomes time in range hypo / hyperglycemia frequency Prediction feature available in a future release Data for presentation purposes only 2018 ADA Orlando, FL 14
15 SMART CGM HELPS MDI PATIENTS MAKE SMARTER DECISIONS SO THEY CAN FOCUS ON LIFE, NOT ON LEVELS In-Room Video URL: Investor Day 15
16 CLINICAL OBSERVATIONS BETTER BEHAVIOR LEADING TO POSITIVE OUTCOMES AGGREGATE DATA p =0.01 p <0.001 p < ,356 Total Users Calendar days Time In Range 30 mins per day 6 mins per day 231 Users with 2+ weeks of data after using Sugar.IQ Time >180 mg/dl (Avg. per day) Time <70 mg/dl (Avg. per day) INSIGHTS p <0.001 p < ,761 Insights Generated 655 Hypo-related Insights Hypo + Hyper 1.22 episodes 0.95 episodes 699 Hyper-related Insights # of episodes High Episodes / Month (180 mg/dl > 120 mins) Low Episodes / Month (70 mg/dl > 20 mins) Usage of Sugar.IQ app was analyzed based on data from 256 randomly offered real-world MiniMed 530G users from April to August ADA Orlando, FL 16
17 SUGAR.IQ DIABETES ASSISTANT AI PERSONALIZATION = ACTIONABLE INSIGHTS AI-Based Assistant continually analyzes multiple data sources Retrospective Insights reveal hidden patterns INSULIN INSIGHTS FOOD INSIGHTS MOTIVATIONAL INSIGHTS ROUTINE & TIME OF DAY INSIGHTS Glycemic Assist lets patients track glucose response to new foods and routines My Data tracks time in range and other key metrics in real time LOW SG FORECAST Hypo prediction up to 4 hours in advance 2018 ADA Orlando, FL 17
18 BUILDING A COMPLETE ECOSYSTEM FOR MDI PATIENTS Launched Near Long GOALS SENSOR Guardian Connect + Guardian Sensor 3 Arm label, 9% MARD Project Harmony Adaptive calibrations & non-adjunctive Project Unity Smaller, no cals, 10-14d, disposable Comfortable & Reliable 360 o DATA Patient Logging Multiple in-app tools meals, activity, insulin Automated Capture Insulin dose capture + advanced food logging Contextual Fully automated based on contextual signals 360 o Patient View INSIGHTS Sugar.IQ (US) Actionable glucose insights Glucose Prediction AI-based 4 hour forecast ~90% accuracy Therapy Guidance AI-based meal and correction bolus Know. Predict. Coach. ECOSYSTEM Physician Web-based data mgmt. Patient Care Plans Interactive HCP+patient for remote therapy optimization Population Management Population-level management tools Linked Ecosystem & Optimized outcomes Note: future concepts; not investigational nor commercially available 2018 ADA Orlando, FL 18
19 SHERI DODD VICE PRESIDENT & GM NON-INTENSIVE DIABETES THERAPIES 2018 ADA Orlando, FL 19
20 EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT DISEASE STATE REGIMEN PREVALENCE DIET & EXERCISE 90M NDT ORALS 90M TYPE 2 Diagnostic & intermittent CGM <1% share <1% penetration New market opportunity BASAL 15M PREMIX 15M GOAL Glucose as a Vital Sign MDI 16M TYPE 1 PUMPS 1.1M NDT Non-intensive Diabetes Therapies Patients Served: T2D Call point: PCPs/GPs Solutions: Professional diagnostic CGM 2018 ADA Orlando, FL 20
21 MEDTRONIC CARE MANAGEMENT SERVICES + NON-INTENSIVE DIABETES THERAPIES ADDRESSING THE NEEDS OF THE CHRONIC COMORBID POPULATION 5,600,000+ Telehealth Patient Months 19 Years Developing the Telehealth Market 95,000+ Members/ patients on Service MCMS NDT Integrated Care Management Nurses, Certified Heart Failure Nurses >20 Disease Management Protocols (physical and mental health) Clinical decision support software 2018 ADA Orlando, FL 21
22 MEDTRONIC CARE MANAGEMENT SERVICES + NON-INTENSIVE DIABETES THERAPIES SYNERGY EXAMPLE RIGHT TOOLS RIGHT PATIENTS MCMS identifies Complex Chronic Comorbid Population using risk stratification methodology HIGHEST ACUITY Remote Patient Monitoring Guardian Connect MiniMed 670G MCMS further Risk Stratifies populations into Cohorts (inc. HF, COPD, HTN, Diabetes) Further Risk Stratification to identify clinical decision support tools to inform care pathway MID-LEVEL ACUITY Guardian Connect / Sugar.IQ Inner Circle Patient Coaching Remote Patient Monitoring LOW ACUITY ipro2 with Pattern Snapshot + FoodPrint Patient Coaching IMPROVE OUTCOMES LOWER COSTS 2018 ADA Orlando, FL 22
23 NON-INTENSIVE DIABETES THERAPIES THERAPY INNOVATION PIPELINE INVESTING FOR FUTURE GROWTH LAUNCHED AND DRIVING CURRENT GROWTH FY19 / FY20 BEYOND Medtronic ipro Intelligent Therapy Recommendations Personalized Guidance Real Time Coaching Medtronic Envision Pro Medtronic Envision Real Time Note: investigational device only Note: Future concepts; not investigational nor commercially available 2018 ADA Orlando, FL 23
24 HOOMAN HAKAMI EXECUTIVE VICE PRESIDENT & PRESIDENT DIABETES GROUP 2018 ADA Orlando, FL 24
25 OUR VALUE PROPOSITION ACROSS ALL BUSINESSES Therapy Innovation Decision Support Patient Engagement VBHC Contracting 2018 ADA Orlando, FL 25
26 DIABETES GROUP CONSISTENT, SUSTAINABLE, GROWTH ABOVE CORPORATE AVERAGE GROWTH DRIVERS CATEGORY SALES 1 MARKET CAGR 2 THERAPY INNOVATION Closed Loop as Standard-of-Care Increased CGM attachment rates; Drive MDI conversions; International expansion ~$3.5B ~10% CONSISTENT EXECUTION GLOBALIZATION ECONOMIC VALUE Sustained Growth Above Corporate Average Launched Stand-Alone CGM Smart CGM system focused on outcomes Expansion into Type 2 Increase diagnostic CGM glucose as a vital sign in the management of T2 ~$1B ~26% ~$0.1B ~70% ENTERPRISE EXCELLENCE Globalization & Enterprise Excellence Clinics & care management expansion globally Leverage MDT Footprint for CGM & Customer Care 1. FY18 market estimates 2. FY17-FY22 growth estimates 2018 ADA Orlando, FL 26
27 ADA 2018 JUN 25, 2018 ORLANDO, FLORIDA
28 APPENDIX
29 2018 ADA Orlando, FL 29
INVESTOR DAY JUN 5, 2018 NEW YORK CITY
INVESTOR DAY JUN 5, 2018 NEW YORK CITY HOOMAN HAKAMI EVP AND GROUP PRESIDENT DIABETES GROUP FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationQUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?
500 1 QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3? WHAT ADDITIONAL DATA ARE NEEDED? AACE/ACE CGM Consensus Conference:
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationCOMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCanaccord Growth Conference August confidently live life with ease
Canaccord Growth Conference August 2018 confidently live life with ease Forward-Looking Statements This presentation contains forward-looking statements that are not purely historical regarding Senseonics
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCOMPANY OVERVIEW. October 12, 2017
COMPANY OVERVIEW October 12, 2017 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationUSING THE MINIMED 670G SYSTEM
USING THE MINIMED 670G SYSTEM Instructions for the Experienced MiniMed 630G System User USING THE MINIMED 670G SYSTEM: INSTRUCTIONS FOR THE EXPERIENCED USER Checklist for starting on your MiniMed 670G
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationUSING THE MINIMED 670G SYSTEM. Instructions for the Experienced MiniMed 630G System User
USING THE MINIMED 670G SYSTEM Instructions for the Experienced MiniMed 630G System User This is a supplemental guide. For complete instructions and safety information, please see your MiniMed 670G System
More informationDexcom Current and Future Technology Innovations. Jorge Valdes Chief Technical Officer
Dexcom Current and Future Technology Innovations 2015 Jorge Valdes Chief Technical Officer G5 App Sensor (Same as G4) Indicated for adults and children down to Age 2 years Tiny insertion needle (26Ga)
More informationDIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson
DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson March 3 rd, 2018 Who is this guy? Accelerating Progress 1 Oh that guy! Accelerating Progress 2 STATE OF T1D CARE
More informationMORE TIME TO BE. The MiniMed 670G system. Less time thinking about managing your diabetes. *1 More time focusing on your day. 2,3
MORE TIME TO BE Leanne. MiniMed TM 670G Ambassador The MiniMed 670G system Less time thinking about managing your diabetes. *1 More time focusing on your day. 2,3 *Some user interaction required. THE SYSTEM
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationWOULD YOU LIKE TO REDUCE THE FEAR OF HYPOGLYCAEMIA FOR YOUR PATIENTS?
WOULD YOU LIKE TO REDUCE THE FEAR OF HYPOGLYCAEMIA FOR YOUR PATIENTS? THE ONLY SYSTEM CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA MINIMED 640G SYSTEM WITH SMARTGUARD TECHNOLOGY 1 HYPOGLYCAEMIA IS CHALLENGING
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationAbbott FreeStyle Libre Pro System
, the Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationINSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. Waterproof to a depth
More informationTHE ONLY SYSTEM^ CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA
THE ONLY SYSTEM^ CLINICALLY PROVEN TO REDUCE HYPOGLYCAEMIA MINIMED 640G system^ with SmartGuard technology HYPOGLYCAEMIA IS CHALLENGING FOR GLYCAEMIC CONTROL 1 AND quality of life 2 Achieving good glucose
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation November 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationAbbott FreeStyle Libre Pro System
Professional CGM Abbott FreeStyle Libre Pro Reader Kit includes: Reader, USB cable, interactive tutorial on USB, and power adapter, user s manual, Quick Start Guide, Quick Reference Guide Kit includes:
More informationINSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.
INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs. * NOW APPROVED FOR AGES 7 AND UP. MORE TIME HERE TO USING
More informationDISCOVER THE POWER OF CONNECTION MINIMED 640G
DISCOVER THE POWER OF CONNECTION MINIMED 640G INSULIN PUMP THERAPY CHANGING LIVES TODAY Has your child just been diagnosed with insulin dependent diabetes? Or perhaps they ve been on multiple daily injection
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More informationC o n n e c t e d I n s u l i n D e l i v e r y S y s t e m
Technology Innovation Alert C o n n e c t e d I n s u l i n D e l i v e r y S y s t e m 6 July 12 July, 2018 1 4 0 0 Start ups Companies Universities Individuals Interesting Innovation Compliance with
More informationWelcome to CareLink Pro
Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationRELEASED. Clearing your active insulin
To clear all your settings: 1. Make sure the pump is not connected to your body. 2. Go to the Manage Settings screen. Menu > Utilities > Manage Settings 3. Simultaneously press and hold and until the Manage
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationGlucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets
Devices Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets Accuracy Glucometers The ISO (International Organization for
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationDISCOVER THE POWER OF CONNECTION MINIMED 640G
DISCOVER THE POWER OF CONNECTION MINIMED 640G INSULIN PUMP THERAPY CHANGING LIVES TODAY Have you just been diagnosed with insulin dependent diabetes? Perhaps you ve been on multiple daily injection therapy
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2009 Medtronic MiniMed. All rights reserved. 6025274-012_a CareLink Pro Report Reference Guide 0 p.2 Adherence
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationHealthcare for the Emerging Middle Class
Healthcare for the Emerging Middle Class Type 2 diabetes care design in India May 2014 1 When looking for healthcare opportunities in emerging markets, project teams on the ground are less influenced by
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2007 Medtronic MiniMed. All rights reserved. 6025274-0U2 120707 CareLink Pro Report Reference Guide 0 p.2 Sensor
More informationCALIPSO Project. an innovative approach to insulin therapy management
CALIPSO Project an innovative approach to insulin therapy management Preface Our project Preliminary business plan Project Team Calipso Project 2015 Why it should be so hard for diabetics to manage their
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationUnderstanding the CareLink TM Therapy Management Dashboard Report
3 2 1 5 6 7 4 1 This is a great place to start recognizing trends. In this example you may see plenty of events that result in a low glucose trend. A low glucose is identified as a value less than 70mg/dL.
More informationContinuous Glucose Monitoring
Continuous Glucose Monitoring What is Continuous Glucose Monitoring? Blood glucose meters measure glucose in your blood and glucose sensors measure glucose levels in the fluid around the cells They are
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationMember-centered cancer care In Georgia
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationTHE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE
THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE Indicated for type 1 patients 14 and over. Prescription required. WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it
More informationGIVE YOUR PATIENTS CERTAINTY
GIVE CERTAINTY Pictured: The Renouf brothers all live with T1D TECH UPGRADE CGM SUBSCRIPTION INTRODUCING THE TECH UPGRADE CGM SUBSCRIPTION FROM MEDTRONIC HOW SMARTGUARD TM WORKS In Australia people generally
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationBetter Diagnostics for Life
NASDAQ: NMRD Better Diagnostics for Life Corporate Presentation December 2018 Forward-Looking Statement This presentation includes forward-looking statements that are subject to many risks and uncertainties.
More informationValeritas. Cowen Health Care Conference. Corporate Presentation. NASDAQ: VLRX March 12, 2018
Cowen Health Care Conference Valeritas Corporate Presentation NASDAQ: VLRX March 12, 2018 Improving health and simplifying life for people with diabetes NASDAQ: VLRX John Timberlake, CEO Improving health
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes
Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization
More informationObjectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018
Objectives Innovations in Diabetes Care and Management Barbara Walz, RN, BSN, CDE April 26, 2018 1. Briefly discuss the history of diabetes management over the past 100 years 2. Describe the impact of
More informationWOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION
WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION 1,2 MINIMED 640G WITH SMARTGUARD HAVE YOU CONSIDERED THE REAL IMPACT HYPOGLYCAEMIA HAS ON YOUR LIFE?
More informationPATIENT TRAINING CHECKLIST MINIMED 670G SYSTEM
Technical Training Insulin Pump Infusion Set: Insulin Pump Model: BASIC FEATURES Patient has demonstrated understanding of: Button Functions Home Screen Menu review Status Screens Battery type/insertion
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationSCANNER & SERVICES OVERVIEW
SCANNER & SERVICES OVERVIEW Tim Mack VP BUSINESS DEVELOPMENT & GM ITERO 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationPredicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY
Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for
More informationMEDTRONIC PAIN THERAPIES & BRAIN MODULATION INVESTOR BRIEFING JANUARY 17, 2019 NORTH AMERICAN NEUROMODULATION SOCIETY (NANS)
MEDTRONIC PAIN THERAPIES & BRAIN MODULATION INVESTOR BRIEFING NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) JANUARY 17, 2019 RYAN WEISPFENNING VICE PRESIDENT INVESTOR RELATIONS FORWARD LOOKING STATEMENT
More informationContinuous Glucose Monitoring Devices Pharmacy Policy
Line of Business: All Line of Business Effective date: August 16, 2017 Revision date: August 16, 2017 Continuous Glucose Monitoring Devices Pharmacy Policy This policy has been developed through review
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationTechnology in Diabetes Management Irl B. Hirsch, MD University of Washington
Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand
More informationNew inhaler monitoring technologies: what they do and how they are used
Please note, some slides have been removed due to potential copyright restrictions. New inhaler monitoring technologies: what they do and how they are used Paul Colthorpe Global Program Head, Novartis
More informationCARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT CARELINK REPORTS GUIDE
CARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT CARELINK REPORTS GUIDE CARELINK PERSONAL ACTIONABLE INSIGHTS FOR BETTER DIABETES MANAGEMENT As part of your diabetes therapy you have
More informationPeople with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT
Position Statement People with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT Diabetes Australia believes that people with diabetes should have choice and access
More informationContinuous Glucose Monitoring
Continuous Glucose Monitoring Information about fully-subsidised continuous glucose monitoring for children and young people with type 1 diabetes Continuous glucose monitoring (CGM) can help in managing
More informationJDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director
JDRF RESEARCH UPDATE Daniel Finan, Ph.D. Research Director March 10, 2018 PRESENTER Daniel Finan Biomedical engineer B.S. Chemical Engineering University of Colorado, 2003 Ph.D. Chemical Engineering UC
More informationMEDTRONIC SCIENTIFIC PROGRAM
SCIENTIFIC PROGRAM ATTD 2017 15 th - 18 th PARIS, FRANCE Our vision at Medtronic is to transform diabetes care by working closely with you, so people living with diabetes can enjoy greater freedom and
More information10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:
DEXCOM G5 MOBILE CGM COMPATIBLE B 100% 235 u INSULIN ON BOARD: OPTIONS 10:20 AM March 5, 2017 400 350 300 250 200 150 100 50 1.1 u 1:09 hrs BOLUS 124 mg/dl 3 HRS The pump that gets updated, not outdated.
More informationLive life, less complicated. InPen MOBILE APP. Healthcare Provider INSTRUCTIONS FOR USE. CompanionMedical.com
InPen MOBILE APP Healthcare Provider INSTRUCTIONS FOR USE TABLE OF CONTENTS Introduction...3 InPen Mobile App...3 Intended Use...3 Indications for Use...3 Contraindications...3 Start Orders...4 General
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationMINIMED 640G WITH SMARTGUARD GIVES YOU CONFIDENCE TO TAKE CONTROL OF YOUR DIABETES
MINIMED 640G WITH SMARTGUARD GIVES YOU CONFIDENCE OF YOUR DIABETES HAVE YOU CONSIDERED THE REAL IMPACT HYPOS HAVE ON YOUR LIFE? AN ESTIMATED 1 HOUR EVERY DAY IS LOST TO THE MANAGEMENT OF 43% OF PEOPLE
More informationPROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY
PROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY Situations Requiring Special Consideration and Resource Documents Second Edition MiniMed 67G System Medical Education TABLE OF CONTENTS A PROTOCOL FOR HYBRID
More informationNEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center
NEWS BRIEFING Advances in Technology moderated by: Irl Hirsch, MD University of Washington Medical Center 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in
More informationValeritas. Corporate Presentation. NASDAQ: VLRX October Improving health and simplifying life for people with diabetes Valeritas, Inc.
Valeritas Corporate Presentation NASDAQ: VLRX October 2018 Improving health and simplifying life for people with diabetes Forward Looking Statements This presentation shall not be deemed an offer to sell
More informationPolicy for Continuous Glucose Monitoring for Type 1 Diabetic Paediatric Patients (<18 years of age)
Policy for Continuous Glucose Monitoring for Type 1 Diabetic Paediatric Patients (
More informationImportant information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar
More informationHow to Transfer Your Settings
How to Transfer Your Settings for your Replacement MiniMed 530G System Let s get started! Step 1: Before you send your original pump back, copy your current settings onto the Insulin Pump Settings Form.
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationState of California Health and Human Services Agency Department of Health Care Services
State of California Health and Human Services Agency Department of Health Care Services JENNIFER KENT Director EDMOND G. BROWN JR Governor DATE: N.L.: 03-0317 Index: Benefits TO: ALL COUNTY CALIFORNIA
More information